Pharmacyclics (PCYC) Worth Up to $274/Share in Takeout - Nomura
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Goldman Sachs Downgrades Pharmacyclics (PCYC) to Neutral
February 27, 2015 6:32 AM ESTGoldman Sachs downgraded Pharmacyclics (NASDAQ: PCYC) from Buy to Neutral.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $217.82 yesterday.
... MoreCredit Suisse Downgrades Pharmacyclics (PCYC) to Neutral
February 27, 2015 6:26 AM ESTCredit Suisse downgraded Pharmacyclics (NASDAQ: PCYC) from Outperform to Neutral with a price target of $233.00 (from $163.00) on valuation following the recent surge on takeover reports.
Analyst J. Kantor thinks the $17-18 billion target range discussed adequately reflects the value of the Imbruvica... More
Pharmacyclics (PCYC) PT Raised to $240 at Baird; Sees 'Fire Behind This Smoke'
February 26, 2015 8:59 AM ESTBaird analyst Brian Skorney reiterated an Outperform rating and boosted his price target on Pharmacyclics (NASDAQ: PCYC) to $240.00 (from $200.00) following takeover reports.
Skorney commented, "We really struggled over whether or not to downgrade following the share price surge off of yesterday's Bloomberg article. Despite our initial temptation to take... More
WallachBeth Capital Downgrades Pharmacyclics (PCYC) to Hold
February 26, 2015 8:07 AM ESTWallachBeth Capital downgraded Pharmacyclics (NASDAQ: PCYC) from Buy to Hold.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $220.22 yesterday.
... MorePharmacyclics (PCYC) Could Fetch $19B - FT
February 25, 2015 2:50 PM ESTPharmacyclics (NASDAQ: PCYC) previously rumored sale to Johnson & Johnson (NYSE: JNJ) could fetch $19 billion, according to reports in the Financial Times.
... MoreDeutsche Bank Downgrades Pharmacyclics (PCYC) to Hold
February 25, 2015 2:08 PM ESTDeutsche Bank downgraded Pharmacyclics (NASDAQ: PCYC) from Buy to Hold with a price target of $235 (from $205). The change follows rumors about a potential acquisition. Analyst Robyn Karnauskas sees takeout valuation at $226-256 per share.
"Every addl $1B in... More
Bernstein Skeptical of Pharmacyclics (PCYC) Takeover Report - Feuerstein
February 25, 2015 1:24 PM ESTTheStreet's biotech watcher Adam Feuerstein notes that Bernstein trading desk is skeptical of today's takeover rumors on Pharmacyclics (NASDAQ: PCYC).
Bernstein trading desk reaction to $PCYC takeout rumor. Skeptical. pic.twitter.com/SxiF83x0mh
Adam Feuerstein (@adamfeuerstein) February 25, 2015... MorePharmacyclics (PCYC) Said to Weigh Possible Sale (JNJ) (NVS)
February 25, 2015 12:42 PM EST(Updated - February 25, 2015 12:54 PM EST)
Pharmacyclics (Nasdaq: PCYC) said to weigh sale, according to Bloomberg.
UPDATE - Market speculation has Pharmacyclics getting $17 to $18 billion in a buyout, which is 13 to 20 percent above recent trading levels.
Potential suitors... More
